tetano
Editor, Senior Moderator
J Eur Acad Dermatol Venereol. 2020 May 9. doi: 10.1111/jdv.16613. [Epub ahead of print]
Acute Generalized Exanthematous Pustulosis with Erythema Multiforme-Like lesions in a COVID-19 woman.
Robustelli Test E[SUP]1[/SUP], Vezzoli P[SUP]2[/SUP], Carugno A[SUP]2[/SUP], Raponi F[SUP]2[/SUP], Gianatti A[SUP]3[/SUP], Rongioletti F[SUP]1[/SUP], Sena P[SUP]2[/SUP].
Author information
Abstract
The antimalarials, Chloroquine and Hydroxychloroquine (HCQ), and the antivirals Lopinavir/Ritonavir have been recently recorded as having anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) effects.[SUP]1[/SUP] In particular, regarding Italy, one of the countries most affected by the pandemic, the Italian Society of Infectious and Tropical disease (Lombardy section) has recommended the use of HCQ for treatment of coronavirus disease 2019 (COVID-19).
This article is protected by copyright. All rights reserved.
KEYWORDS:
Acute Generalized Exanthematous Pustulosis (AGEP); COVID-19; Drug reaction; Hydroxychloroquine (HCQ); Skin; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
PMID:32386448DOI:10.1111/jdv.16613
Acute Generalized Exanthematous Pustulosis with Erythema Multiforme-Like lesions in a COVID-19 woman.
Robustelli Test E[SUP]1[/SUP], Vezzoli P[SUP]2[/SUP], Carugno A[SUP]2[/SUP], Raponi F[SUP]2[/SUP], Gianatti A[SUP]3[/SUP], Rongioletti F[SUP]1[/SUP], Sena P[SUP]2[/SUP].
Author information
Abstract
The antimalarials, Chloroquine and Hydroxychloroquine (HCQ), and the antivirals Lopinavir/Ritonavir have been recently recorded as having anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) effects.[SUP]1[/SUP] In particular, regarding Italy, one of the countries most affected by the pandemic, the Italian Society of Infectious and Tropical disease (Lombardy section) has recommended the use of HCQ for treatment of coronavirus disease 2019 (COVID-19).
This article is protected by copyright. All rights reserved.
KEYWORDS:
Acute Generalized Exanthematous Pustulosis (AGEP); COVID-19; Drug reaction; Hydroxychloroquine (HCQ); Skin; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
PMID:32386448DOI:10.1111/jdv.16613